Ensifentrine delivered by pMDI met all of the primary and secondary lung ... hours) to report in mL, a measure of the aggregate effect over 12 hours or 4 hours. ... Ensifentrine (RPL554) is an investigational, first-in-class, inhaled, dual ...
Source link
Categories:
Asthma
Comments Off on Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
